Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Journal
Lancet (London, England)
Journal Volume
401
Journal Issue
10391
Date Issued
2023-06-03
Author(s)
Kelley, Robin Kate
Ueno, Makoto
Yoo, Changhoon
Finn, Richard S
Furuse, Junji
Ren, Zhenggang
Yau, Thomas
Klümpen, Heinz-Josef
Chan, Stephen L
Ozaka, Masato
Verslype, Chris
Bouattour, Mohamed
Park, Joon Oh
Barajas, Olga
Pelzer, Uwe
Valle, Juan W
Yu, Li
Malhotra, Usha
Siegel, Abby B
Edeline, Julien
Vogel, Arndt
Abstract
Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. The standard-of-care treatment for advanced biliary tract cancer is chemotherapy with gemcitabine and cisplatin. Because most biliary tract cancers have an immune-suppressed microenvironment, immune checkpoint inhibitor monotherapy is associated with a low objective response rate. We aimed to assess whether adding the immune checkpoint inhibitor pembrolizumab to gemcitabine and cisplatin would improve outcomes compared with gemcitabine and cisplatin alone in patients with advanced biliary tract cancer.
Type
journal article